Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros Corporation has demonstrated a positive financial trajectory, with other income increasing to $2.1 million due to higher interest income from an enhanced cash balance, indicating robust liquidity. The authorization of a $100 million open-ended share repurchase program reflects management's confidence in the company's financial stability and strategic direction. Moreover, the clinical success of narsoplimab, which has shown a statistically significant survival advantage in treated patients, positions Omeros favorably within the competitive landscape of complement-targeting therapies, bolstering its prospects for future growth.

Bears say

Omeros Corp has demonstrated a decline in research and development expenses, reported at $10.1 million for Q3, which reflects the wind-down of prior clinical studies. This reduction in R&D investment raises concerns about the company’s commitment to advancing its drug pipeline, particularly for its lead candidate, narsoplimab. The strategic cessation of earlier trials may indicate potential challenges in achieving necessary clinical milestones, thereby contributing to a negative outlook for the stock.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.